Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST. The study consists of two parts: dose escalation (phase I) and dose expansion (phase II).

tyrosine
imatinib
blu-285
kinase inhibitor
pdgfra gene
  • 0 views
  • 19 Feb, 2024
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

This study will assess the safety, efficacy, and pharmacokinetics of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST).

tyrosine
gilbert's syndrome
imatinib
major surgery
platelet count
  • 0 views
  • 19 Feb, 2024
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)

imatinib
platelet count
international normalized ratio (inr)
sunitinib
diastolic blood pressure
  • 0 views
  • 19 Feb, 2024
A Study of DCC-2618 (Ripretinib) Evaluating Efficacy Safety and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.This study will enroll approximately 35 subjects in up to 10 sites in China mainland, and …

gastrointestinal stromal tumor
dcc-2618
measurable disease
stromal tumor
ripretinib
  • 0 views
  • 19 Feb, 2024